In Vivo is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gryphon Pharmaceuticals Inc.

Division of Osiris Therapeutics Inc.

Latest From Gryphon Pharmaceuticals Inc.

Parvus Seeks Autoimmune Answers Through Restoring Immune Tolerance

Emerging Company Profile: Partnered with Novartis on a nanoparticle candidate for type 1 diabetes, Parvus develops its proprietary Navacims to help the body’s immune system differ between a pathogen and itself.

StartUps and SMEs Business Strategies

Proteomics: Business or Add-On?

Advocates of proteomics argue that without an understanding of protein interactions, drug researchers will be attempting to paint Old Masters with an incomplete set of genomic paint-by-number instructions.
BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Osiris Therapeutics Inc.
  • Senior Management
  • James S Burns, Chmn. & CEO
  • Contact Info
  • Gryphon Pharmaceuticals Inc.
    Phone: (410) 522-5005
    2001 Aliceanna St.
    Baltimore, MD 21231-2001
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register